Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada

Vaccine

Volumn 32, Issue 42, 2014, Pages 5436-5446

  Tu, Hong Anh T ^a   Deeks, Shelley L ^b,c   Morris, Shaun K ^c,d   Strifler, Lisa ^e   Crowcroft, Natasha ^b,c   Jamieson, Frances B ^b,f   Kwong, Jeffrey C ^b,c,f,g,h   Coyte, Peter C ^a,i   Krahn, Murray ^a,c,h,i   Sander, Beate ^a,b,g,i  

^a UNIVERSITY OF TORONTO   (Canada)

^b PUBLIC HEALTH ONTARIO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

Communicable diseases; Cost and cost analysis; Economics; Neisseria meningitidis; Serogroup B; Vaccines

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; BACTERIAL STRAIN; CANADA; CHILDHOOD DISEASE; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEBRILE CONVULSION; FEVER; HEALTH CARE COST; HERD IMMUNITY; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MARKOV MODEL; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; PUBLIC HEALTH INSURANCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STATISTICAL MODEL; VACCINATION; COST BENEFIT ANALYSIS; ECONOMICS; MENINGOCOCCAL INFECTIONS; PREVENTIVE HEALTH SERVICE; PROBABILITY;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MARKOV CHAINS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; ONTARIO; QUALITY-ADJUSTED LIFE YEARS;

EID: 84911005070     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.096     Document Type: Article

References (36)

1. Harrison L.H., Pelton S.I., Wilder-Smith A., Holst J., Safadi M.A.P., Vazquez J.A., et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011, 29:3363-3371.
2. Halperin S.A., Bettinger J.A., Greenwood B., Harrison L.H., Jelfs J., Ladhani S.N., et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012, 30(Suppl. 2):B26-B36.
3. Dang V., Jamieson F.B., Wilson S., Rawte P., Crowcroft N.S., Johnson K., et al. Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. BMC Infect Dis 2012, 12:202.
4. Health Protection Agency UK. Meningococcal disease epidemiological data, 2011.
5. Newswire Canada. Health Canada Approves Bexsero*, the First Vaccine Available to Prevent Meningococcal Serogroup B (MenB) (1,2) 2013.
6. Novartis media release. Novartis vaccine Bexsero® approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis, 2013.
7. Novartis media release. Novartis supplies MenB vaccine, Bexsero®, to Princeton University to help protect students from potentially deadly outbreak, 2013.
8. Novartis media release. Novartis receives EU approval for Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe, 2013.
9. Vesikari T., Esposito S., Prymula R., Ypma E., Kohl I., Toneatto D., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381:825-835.
10. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
11. Gossger N., Snape M.D., Yu L.-M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307:573-582.
12. Pouwels K.B., Hak E., van der Ende A., Christensen H., van den Dobbelsteen G.P.J.M., Postma M.J. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother 2013, 9:1129-1138.
13. Christensen H., Hickman M., Edmunds W.J., Trotter C.L. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013, 31:2638-2646.
14. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies, n.d.
15. Walker D.G., Hutubessy R., Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010, 28:2356-2359.
16. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making n.d.;32:690-700.
17. Viner R.M., Booy R., Johnson H., Edmunds W.J., Hudson L., Bedford H., et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 2012, 11:774-783.
18. Bettinger J.A., Scheifele D.W., Halperin S.A., Vaudry W., Findlow J., Borrow R., et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013.
19. Kimura M, Vesikari T, Prymula R. Persistence of the immune response to an investigational multicomponent meningococcal serogroup B (4CMenB) vaccine following priming in infants or toddlers. 7th World Congr. World Soc. Pediatr. Infect. Dis., Melbourne, Australia: n.d.
20. Public Health Agency of Canada Final Report to Outcomes from the National Consensus Conference for Vaccine-Preventable Diseases in Canada. Canada Commun Dis Rep 2008.
21. Carroll A.E., Downs S.M. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr 2009, 155. 21-25.e5.
22. Kuppermann M., Nease R.F., Ackerson L.M., Black S.B., Shinefield H.R., Lieu T.A. Parents' preferences for outcomes associated with childhood vaccinations. Pediatr Infect Dis J 2000, 19:129-133.
23. Mittmann N., Trakas K., Risebrough N., Liu B.A. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999, 15:369-376.
24. Poley M.J., Brouwer W.B.F., van Exel N.J.A., Tibboel D. Assessing health-related quality-of-life changes in informal caregivers: an evaluation in parents of children with major congenital anomalies. Qual Life Res 2012, 21:849-861.
25. Ministry of Health and Long-term Care Ontario Health Insurance (OHIP) Schedule of Benefits and Fees 2013.
26. Public Health Agency. Supplement: Guidelines for the Prevention and Control of Meningococcal Disease. Canada Commun Dis Report Rep No 31S1 n.d.
27. Ontario Drug Benefit Formulary. Ontario Drug Benefit Formulary/Comparative Drug Index n.d.
28. Tolomeo O., Buffett C., Richardson E. Management of a cluster of cases of invasive group C Neisseria meningitidis infections in the Hamilton-Wentworth region - Ontario. Can Commun Dis Rep 1998, 24:122-126.
29. Statistics Canada. Consumer Price Index, n.d.
30. OCCI. Ontario Case Costing Initiative, n. d.
31. Cohen E., Berry J.G., Camacho X., Anderson G., Wodchis W., Guttmann A. Patterns and costs of health care use of children with medical complexity. Pediatrics 2012, 130:e1463-e1470.
32. John T.J., Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 2000, 16:601-606.
33. Bennett J.E., Sumner W., Downs S.M., Jaffe D.M. Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med 2000, 154:43-48.
34. Read R.C., Baxter D., Chadwick D.R., Faust S.N., Finn A., Gordon S.B., et al. Impact of Quadrivalent Conjugate (MenACWY- CRM) and Serogroup B (4CMenB) Meningococcal Vaccines on Meningococcal Carriage in English University Students. Poster Sess. Present. Meningitis Septicaemia Child. Adults 2013.
35. Delbos V., Lemée L., Bénichou J., Berthelot G., Deghmane A.-E., Leroy J.-P., et al. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine 2013, 31:4416-4420.
36. U.S. Census Bureau. The 2012 Statistical Abstract - Births, Deaths, Marriages, & Divorces: Life Expectancy, 2014.